According to a new report published by Introspective Market Research, titled, “Allergy Diagnostics and Therapeutics Market by Product, Allergen Type, and End-User,” The Global Allergy Diagnostics and Therapeutics Market Size Was Valued at USD 5.86 Billion in 2024 and is Projected to Reach USD 17.93 Billion by 2035, Growing at a CAGR of 10.71% From 2025–2035.
The Allergy Diagnostics and Therapeutics market encompasses a comprehensive range of tools and treatments used to identify specific allergens and manage allergic diseases. The diagnostics segment includes in-vitro tests (specific IgE blood tests) and in-vivo tests (skin prick tests, patch tests). The therapeutics segment includes antihistamines, corticosteroids, leukotriene inhibitors, biologic drugs, and allergen immunotherapy (AIT). The integrated approach offers a critical advantage over empiric treatment by enabling precision medicine: accurate diagnosis allows for targeted avoidance strategies and selection of the most effective, personalized therapy, moving beyond one-size-fits-all symptom management to address the root cause.
The paramount growth driver for the allergy market is the global "allergy epidemic," characterized by a steep, multi-decade rise in the prevalence of allergic diseases across all age groups, particularly in industrialized and urbanizing regions. This surge is attributed to complex environmental and lifestyle factors, including the "hygiene hypothesis," increased exposure to air pollution and environmental triggers, and dietary changes. The result is a massive and expanding patient population suffering from conditions like allergic rhinitis, asthma, food allergies, and eczema. This creates sustained, non-discretionary demand for both accurate diagnostic tools to identify specific triggers and effective therapeutic interventions to manage symptoms and improve quality of life, driving continuous growth across both segments of the market.
A significant market opportunity lies in the convergence of advanced diagnostics with next-generation biologics and personalized allergen immunotherapy. The field is moving towards component-resolved diagnostics (CRD) using microarray technology, which can pinpoint specific allergenic proteins, enabling ultra-precise risk assessment and therapy selection. This precision directly feeds the growing market for targeted biologic therapies (monoclonal antibodies like omalizumab, dupilumab) that block specific immune pathways (IgE, IL-4/IL-13) in severe allergic asthma and dermatitis. Furthermore, innovation in allergen immunotherapy (AIT), including sublingual tablets and peptides, offers curative potential. Companies that develop integrated diagnostic-therapeutic platforms, using diagnostic results to stratify patients for the most appropriate advanced therapy, will capture the highest value in this evolving market.
Allergy Diagnostics and Therapeutics Market, Segmentation
The Allergy Diagnostics and Therapeutics Market is segmented on the basis of Product, Allergen Type, and End-User.
Product
The Product segment is divided into Diagnostics and Therapeutics. Among these, the Therapeutics sub-segment accounted for the highest market share in 2024. Therapeutics dominates due to the chronic nature of allergic diseases, which require ongoing, often daily, medication for symptom control. This includes a large volume of widely prescribed drug classes like antihistamines and corticosteroids. Furthermore, the introduction of high-cost, targeted biologic drugs for severe conditions and the expanding use of allergen immunotherapy (AIT) have significantly increased the average revenue per patient, solidifying the therapeutics segment as the larger revenue generator.
Allergen Type
The Allergen Type segment is further classified into Inhaled, Food, Drug, and Others. Among these, the Inhaled Allergens sub-segment (e.g., pollen, dust mites, mold, pet dander) accounted for the highest market share in 2024. Inhaled allergies are the most common type globally, driving the vast majority of cases of allergic rhinitis (hay fever) and allergic asthma. The high prevalence, seasonal recurrence, and significant impact on daily life and productivity create a massive, consistent demand for both diagnostics (to identify triggers) and therapeutics (for symptom relief and disease modification), making this the largest segment by allergen type.
Some of The Leading/Active Market Players Are-
• Thermo Fisher Scientific Inc. (US) [Phadia]
• Danaher Corporation (US) [Hycor Biomedical]
• Siemens Healthineers AG (Germany)
• bioMérieux SA (France)
• Omega Diagnostics Group PLC (UK)
• HollisterStier Allergy (US)
• ALK-Abelló A/S (Denmark)
• Stallergenes Greer (UK)
• GlaxoSmithKline plc (UK)
• Sanofi (France)
• Merck & Co., Inc. (US)
• and other active players.
Key Industry Developments
In January 2025, Thermo Fisher Scientific launched its next-generation ImmunoCAP™ ISAC® microarray platform with an expanded allergen component library. The update includes novel food and environmental allergen components, aiming to provide even more detailed molecular allergy profiles to better predict cross-reactivity and guide personalized treatment decisions, including suitability for specific allergen immunotherapy.
In March 2024, the FDA approved a new high-dose, rapid-updosing sublingual immunotherapy (SLIT) tablet for ragweed pollen allergy. The tablet offers a shorter build-up phase to maintenance dosing compared to traditional products, improving patient convenience and adherence, and represents a significant advance in the accessibility and appeal of curative AIT treatments.
Key Findings of the Study
• The Therapeutics product segment and Inhaled Allergen type dominate the market.
• North America is the largest regional market, driven by high allergy prevalence and advanced healthcare adoption.
• The key growth driver is the rapidly increasing global prevalence of allergic diseases (the "allergy epidemic").
• Major trends include the shift towards component-resolved diagnostics and the growing adoption of biologics and advanced allergen immunotherapy.
